Leg-Reg Briefing March 2018: Congress Set to Recess This Week Final Call Letter, Part D Rule Expected April 2nd State Legislative and Advocacy Activity
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate Bill 350. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate Bill 92. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of House Bill 4524. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate Bill 32. We strongly support the language in the Bill which allows a pharmacist to substitute an FDA approved “interchangeable biological product”.
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate Bill 197. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.